Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Growth Analysis, By product(cfDNA and FCMB), By End users(trisomy detection, microdeletion detection) - Industry Forecast 2024-2031

Non-Invasive Prenatal Testing (NIPT) Market size was valued at USD 3.47 billion in 2019 and is poised to grow from USD 3.8 billion in 2023 to USD 7.92 billion by 2031, growing at a CAGR of 9.61% in the forecast period (2024-2031).

Non-Invasive Prenatal Testing (NIPT) Market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. Due to the broad range of product offers and strong distribution networks of big corporations in developed and developing countries, this market is consolidated. The top competitors in the market right now are Illumina, Inc., Sequenom Laboratories, LabCorp Inc., and Natera. It is anticipated that several aspects, such as active research and development efforts and a greater emphasis on producing cutting-edge products, will aid in maintaining their positions in the market. Other significant players, including YOURGENE HEALTH, Eurofins, LifeCodexx GmbH, F. Hoffmann-La Roche, and Perkin Elmer, Inc., intend to increase their market share through the implementation of fresher tactics, such as investments in the creation of innovative technologies for the early detection of chromosomal abnormalities and partnerships with key players and research institutions. 'Illumina, Inc.', 'Natera, Inc.', 'BGI Genomics Co., Ltd.', 'F. Hoffmann-La Roche AG', 'Thermo Fisher Scientific Inc.', 'Agilent Technologies Inc.', 'GE Healthcare', 'Pacific Biosciences of California Inc.', 'Sequenom Laboratories (LabCorp)', 'Qiagen N.V.', 'LifeCodexx AG', 'NIPD Genetics', 'Yourgene Health plc', 'PerkinElmer Inc.', 'Eurofins LifeCodexx GmbH', 'Igenomix S.L.', 'Verinata Health, Inc.', 'Ariosa Diagnostics, Inc. (Roche)', 'SureGenomics, Inc.', 'Berry Genomics Co., Ltd.'

The development of extremely sophisticated screening methods that are highly sensitive and accurate in the early detection of genetic abnormalities in newborns is a continuing priority for a number of businesses. Manufacturers are placing a lot of emphasis on the creation of cutting-edge noninvasive prenatal diagnostics and forming strategic alliances and collaborations to boost their market share. Significant advancements in the detection of aneuploidies in the neonatal population have been made possible by human genome sequencing. For instance, the biotechnology company Progenity, Inc. announced the release of the Resura Prenatal Diagnostic for Monogenic Disease in 2019. It is the first adaptable, noninvasive prenatal test for single-gene illnesses. Many nations are also implementing non-invasive prenatal screening protocols to identify chromosomal problems.

In recent years, prenatal screening or testing has shifted its focus to non-invasive examinations, noting the therapeutic and economic benefits of these procedures. This move was made possible by the market participants' introduction of technologically sophisticated Non Invasive testing and their proven clinical efficacy. In many nations, rules have been put in place to make non-invasive prenatal diagnostics the norm rather than invasive procedures for prenatal screening. Non-invasive diagnostics, for instance, have become the norm for screening pregnant women in the Netherlands. Non-invasive testing has shown rapid rise in usage globally, despite the fact that invasive tests still have their applications in detecting particular conditions.

North America dominated the Non-Invasive Prenatal Testing (NIPT) market in 2021. This is a result of both the rising incidence of Down syndrome in babies and the growing use of noninvasive prenatal diagnostics. Furthermore, the expanding use of these exams in the US and Canada has been greatly influenced by players with a significant geographic presence in the US who provide advanced assessments. The Panorama test, created by Natera, is the only one that can distinguish between maternal and foetal DNA in the target chromosomes. It uses single-nucleotide polymorphism (SNP)-based technology to analyse DNA. In the following years, such innovative advancements are projected to increase usage and fuel market expansion in this region.